Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 5/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022959 | 0.95 | FNTA (0.46) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL13154779 | 0.94 | FOLH1 (0.49) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL14906318 | 0.94 | FOLH1 (0.49) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL29376623 | 0.94 | FOLH1 (0.49) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL29379272 | 0.94 | FOLH1 (0.49) | FOLH1FNTAFNTBPGGT1BLMNA | |
| Hydrochloric Acid SCHEMBL29777366 | 0.92 | FOLH1 (0.48) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL38650655 | 0.91 | FOLH1 (0.47) | FOLH1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30753797 | 0.91 | FOLH1 (0.50) | FOLH1CPB2ERAP2ERAP1LNPEP | |
| SCHEMBL29397210 | 0.90 | GSR (0.50) | FOLH1CPB2ERAP2ERAP1LNPEP | |
| SCHEMBL30011190 | 0.90 | LMNA (0.51) | FOLH1FNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462875-A | Cold tolerance related protein OsCIP1 in booting stage of rice, coding gene and application | 中国农业大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | FOLH1 2678/4885FNTA 4386/4885FNTB 4521/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | FOLH1 2678/4885FNTA 4386/4885FNTB 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.